XLO Xilio Therapeutics, Inc.

1d ago, source: Seeking Alpha

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an ...

Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why

27d ago, source: Hosted on MSN

Xilio Therapeutics Inc (NASDAQ:XLO) shares are surging as the company announced an exclusive license agreement with Gilead Sciences Inc (NASDAQ:GILD) to develop and commercialize Xilio’s Phase 1 ...

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

28d ago, source: Business Insider

March 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people ...

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

23d ago, source: Business Insider

April 01, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people ...

Analyzing the Price-to-Earnings Ratio of Xilio Therapeutics Inc (XLO)

2d ago, source: newsheater

Atlas Venture Fund XI, L.P., the 10% Owner of Xilio Therapeutics Inc, sale 733 shares at $0.64 during a trade that took place back on Feb 08 ’24, which means that Atlas Venture Fund XI, L.P. is ...

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

20d ago, source:

Werewolf Therapeutics, Inc. is developing modified cytokines for cancer treatment, including WTX-124 and WTX-330. Click for ...

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

23d ago, source: Stockhouse

April 01, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living ...

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

28d ago, source: Stockhouse

March 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living ...

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

27d ago, source: Morningstar

Morningstar brands and products Company Get 7 Days Free ...

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

27d ago, source: Nasdaq

As previously announced today, Xilio entered into an exclusive license agreement with Gilead Sciences, Inc. (Gilead) for Xilio’s tumor-activated IL-12 program, including XTX301. Under the terms ...